SCHEMBL4176630

SCHEMBL4176630

COc1ccc(Cl)c2nc(C)ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
MAPT P10636 3/20 0.45
CRHR1 P34998 2/20 0.43
NR4A2 P43354 1/20 0.40
KDM4E B2RXH2 2/20 0.40
KMT2A Q03164 2/20 0.40
S1PR4 O95977 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RAB9A P51151 2/20 0.39
CCR1 P32246 1/20 0.39
CCR5 P51681 1/20 0.39
NPC1 O15118 2/20 0.39
ADORA1 P30542 1/20 0.39
PKM P14618 1/20 0.38
HTT P42858 1/20 0.38
TSHR P16473 1/20 0.37
NQO1 P15559 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16716886 0.98 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL23714063 0.81 MAPT (0.49) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL16716854 0.79 ADORA1 (0.48) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL16717338 0.79 MAPT (0.42) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL4169028 0.75 KDM4E (0.37) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL11557724 0.74 NR4A2 (0.59) MAPTNR4A2KDM4EKMT2AALDH1A1
SCHEMBL874389 0.74 MAPT (0.47) MAPTNR4A2KDM4EKMT2AS1PR4
SCHEMBL10627274 0.74 OPRK1 (0.56) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL4174305 0.74 KMT2A (0.56) MAPTNR4A2KDM4EKMT2AALDH1A1
SCHEMBL28506436 0.73 NPC1 (0.50) PDE4APDE4BPDE4CPDE4DMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3681885-B1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-02-28 EP disclosed
US-20240016795-A1 BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS FORMA THERAPEUTICS INC (US) 2024-01-18 US disclosed
US-20240016795-A1 BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS FORMA THERAPEUTICS INC (US) 2024-01-18 US disclosed
US-11801243-B2 Bromodomain inhibitors for androgen receptor-driven cancers FORMA THERAPEUTICS, INC. (US) 2023-10-31 US disclosed
US-11801243-B2 Bromodomain inhibitors for androgen receptor-driven cancers FORMA THERAPEUTICS, INC. (US) 2023-10-31 US disclosed
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors FORMA THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors FORMA THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-20230061891-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20220169647-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS, INC. 2022-06-02 US disclosed
US-20220162207-A1 INHIBITING CREB BINDING PROTEIN (CBP) FORMA THERAPEUTICS, INC. 2022-05-26 US disclosed
US-20160257692-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2016-09-08 US disclosed
US-9388161-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2016-07-12 US disclosed
US-9388161-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2016-07-12 US disclosed
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2015-08-20 US disclosed
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2015-08-20 US disclosed
WO-2015074064-A2 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BAIR KENNETH W (US) 2015-05-21 WO disclosed
US-20090076274-A1 BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS GLAXO GROUP LIMITED 2009-03-19 US disclosed
US-20060264429-A1 Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders GLAXO GROUP LIMITED (GB) 2006-11-23 US disclosed
EP-1562917-A1 BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS GLAXO GROUP LIMITED (GB) 2005-08-17 EP disclosed
WO-2004046124-A1 BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS GLAXO GROUP LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162207-A1 INHIBITING CREB BINDING PROTEIN (CBP) CREBBP, EP300, CREB1 PDE4A 664/4885PDE4B 787/4885PDE4C 771/4885
US-20240016795-A1 BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS BRDT, AR, BRD4 PDE4A 1808/4885PDE4B 1968/4885PDE4C 1570/4885
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 PDE4A 3733/4885PDE4B 3725/4885PDE4C 3871/4885
US-20220169647-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS EP300, CREBBP, BRD3 PDE4A 1816/4885PDE4B 2162/4885PDE4C 1963/4885
US-20060264429-A1 Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders XDH, CYP4X1, PDHX PDE4A 472/4885PDE4B 527/4885PDE4C 524/4885
US-20090076274-A1 BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS XDH, CYP4X1, PDHX PDE4A 684/4885PDE4B 717/4885PDE4C 761/4885
US-20230061891-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 PDE4A 3733/4885PDE4B 3725/4885PDE4C 3871/4885
US-20160257692-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 PDE4A 3733/4885PDE4B 3725/4885PDE4C 3871/4885
US-11801243-B2 Bromodomain inhibitors for androgen receptor-driven cancers BRDT, AR, BRD4 PDE4A 1808/4885PDE4B 1968/4885PDE4C 1570/4885
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors EP300, CREBBP, BRD3 PDE4A 1816/4885PDE4B 2162/4885PDE4C 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.